trending Market Intelligence /marketintelligence/en/news-insights/trending/eoxwhekvkzl-7dsuklaiqg2 content
BY CONTINUING TO USE THIS SITE, YOU ARE AGREEING TO OUR USE OF COOKIES. REVIEW OUR
PRIVACY & COOKIE NOTICE
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Pluristem to advance blood transplant study

Shareholder Advocates Say New SEC Policy To Prompt Litigation, Less Transparency

Groups Urge Business Roundtable CEOs To Act On New Corporate Purpose Declaration

State of South Korean OTT Video: Subscription

Global Streaming Media Device Sales Forecast To Flatten In 5 Year Outlook


Pluristem to advance blood transplant study

Pluristem Therapeutics Inc. is collaborating with the New York Blood Center to advance studies on its PLX-R18 therapy for umbilical cord blood transplantation.

The study will be funded by a conditional award of $900,000 from the Israel-U.S. Binational Industrial Research and Development Foundation with Pluristem providing the PLX-R18 cells and the NYBC conducting and supporting the studies.